Defence Therapeutics (TSE:DTC)
:DTC
Want to see TSE:DTC full AI Analyst Report?
DTC Stock Chart & Stats
C$0.78
-C$0.03(-4.41%)
At close: 4:00 PM EST
C$0.78
-C$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeC$0.50 - C$1.05
Previous CloseN/A
Volume0.00
Average Volume (3M)68.27K
Market Cap
C$32.13M
Enterprise ValueC$32.67M
Total Cash (Recent Filing)C$947.35K
Total Debt (Recent Filing)C$1.49M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding57,369,970
10 Day Avg. Volume109,889
30 Day Avg. Volume68,269
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-27.77
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformAccum® is a differentiated intracellular-delivery platform that can enhance biologic potency. Platform-level IP provides a durable competitive advantage across modalities, enabling multiple programs to leverage the same core tech and creating long-term optionality if clinical translation succeeds.
Diverse R&D FocusPipeline activity across oncology and infectious disease spreads scientific and commercial risk. Multiple indication focus gives the company several 'shots on goal' for Accum® applications, supporting sustained R&D value creation and reducing dependence on any single program.
Improving Loss And FCF TrendReported annual loss narrowed materially from ~-13.2M to ~-3.5M and TTM free cash flow improved versus prior period. This indicates meaningful cost control and improving cash-conversion trends that, if sustained, reduce near-term funding pressure and extend the runway for clinical programs.
Bears Say
No Commercial RevenueThe company reports zero revenue across annual periods and TTM, meaning no commercial validation or product sales. Structurally, this leaves operations fully dependent on external financing and magnifies execution risk until a product is commercialized or recurring revenue is established.
Negative Shareholders' EquityShareholders' equity turned negative in recent periods, elevating balance-sheet risk. Negative equity reflects accumulated losses or dilution, weakens solvency metrics, complicates leverage interpretation, and makes the company more likely to require financing that could dilute existing holders.
Persistent Cash BurnTTM operating cash flow remains heavily negative (~-4.9M) with ongoing cash burn despite some FCF improvement. Persistent negative cash generation forces dependence on external funding, limits investment flexibility, and raises program-continuity risk if capital markets or financing options tighten.
Defence Therapeutics News
DTC FAQ
What was Defence Therapeutics’s price range in the past 12 months?
Defence Therapeutics lowest stock price was C$0.50 and its highest was C$1.05 in the past 12 months.
What is Defence Therapeutics’s market cap?
Defence Therapeutics’s market cap is C$32.13M.
When is Defence Therapeutics’s upcoming earnings report date?
Defence Therapeutics’s upcoming earnings report date is May 22, 2026 which is in 24 days.
How were Defence Therapeutics’s earnings last quarter?
Defence Therapeutics released its earnings results on Feb 20, 2026. The company reported -C$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.028.
Is Defence Therapeutics overvalued?
According to Wall Street analysts Defence Therapeutics’s price is currently Overvalued.
Does Defence Therapeutics pay dividends?
Defence Therapeutics does not currently pay dividends.
What is Defence Therapeutics’s EPS estimate?
Defence Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Defence Therapeutics have?
Defence Therapeutics has 57,369,970 shares outstanding.
What happened to Defence Therapeutics’s price movement after its last earnings report?
Defence Therapeutics reported an EPS of -C$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.154%.
Which hedge fund is a major shareholder of Defence Therapeutics?
Currently, no hedge funds are holding shares in TSE:DTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Defence Therapeutics
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---